ARTICLE | Company News
Hybridon deal
May 16, 1994 7:00 AM UTC
The agreement applies to other antisense compounds for neurodegenerative diseases that the companies may agree to develop jointly over the next five years. ...
Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
The agreement applies to other antisense compounds for neurodegenerative diseases that the companies may agree to develop jointly over the next five years. ...